Back to search

Article

Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial

2024-08-30

Abstract excerpt

<h4>ABSTRACT</h4> In syngeneic murine breast cancer models, poly(ADP-ribose) polymerase inhibitor (PARPi) and anti-PD-L1 combinations induce deep, sustained responses independent of BRCA1 or BRCA2 mutation (BRCAm) status. We therefore investigated this combination in the AMTEC clinical trial, in which a one-month olaparib run-in was followed by combined olaparib and durvalumab in participants with non-BRCAm met...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
629e4a4a-a966-53b5-b40e-057ff9b332f6
DOI
10.1101/2024.08.29.24312245
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC TrialDOI 10.1101/2024.08.29.24312245
An Omic and Multidimensional Spatial Atlas from Serial Biopsies of an Evolving Metastatic Breast CancerSemantic proximity
An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancerSemantic proximity
Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancersSemantic proximity
Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatmentSemantic proximity
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerSemantic proximity
Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer CellsSemantic proximity
Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerSemantic proximity
Convergent stromal and immune remodeling defines spatial tumor dynamics in PARP inhibitor–resistant high-grade serous ovarian cancerSemantic proximity
Multicenter reverse-phase protein array data integrationSemantic proximity
Standardization of suspension and imaging mass cytometry readouts for clinical decision makingSemantic proximity
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patientsSemantic proximity
Molecular & Translational Biology of the Blood-Based VeriStrat® Proteomic Test Used in Cancer Immunotherapy Treatment GuidanceSemantic proximity
Select a neighboring publication to make it the new centre.